Mitsubishi UFJ Asset Management Co. Ltd. Purchases 26,543 Shares of DexCom, Inc. $DXCM

Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in DexCom, Inc. (NASDAQ:DXCM) by 2.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 1,169,269 shares of the medical device company’s stock after acquiring an additional 26,543 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. owned 0.30% of DexCom worth $77,803,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Trust Co. of Vermont boosted its holdings in DexCom by 14.8% in the fourth quarter. Trust Co. of Vermont now owns 1,122 shares of the medical device company’s stock worth $74,000 after acquiring an additional 145 shares in the last quarter. CVA Family Office LLC boosted its holdings in DexCom by 48.5% in the fourth quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after acquiring an additional 147 shares in the last quarter. IFP Advisors Inc boosted its holdings in DexCom by 24.7% in the third quarter. IFP Advisors Inc now owns 900 shares of the medical device company’s stock worth $61,000 after acquiring an additional 178 shares in the last quarter. Personal CFO Solutions LLC boosted its holdings in DexCom by 5.0% in the third quarter. Personal CFO Solutions LLC now owns 3,864 shares of the medical device company’s stock worth $260,000 after acquiring an additional 185 shares in the last quarter. Finally, Inspire Advisors LLC boosted its holdings in DexCom by 2.5% in the third quarter. Inspire Advisors LLC now owns 7,926 shares of the medical device company’s stock worth $533,000 after acquiring an additional 194 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

DexCom Stock Performance

Shares of DexCom stock opened at $60.91 on Friday. The company has a market cap of $23.50 billion, a PE ratio of 26.03, a price-to-earnings-growth ratio of 1.04 and a beta of 1.40. DexCom, Inc. has a 52 week low of $54.11 and a 52 week high of $89.98. The business has a 50 day moving average price of $65.10 and a 200-day moving average price of $66.29. The company has a quick ratio of 1.64, a current ratio of 1.95 and a debt-to-equity ratio of 0.42.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, April 30th. The medical device company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.47 by $0.09. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.17 billion. DexCom had a return on equity of 33.33% and a net margin of 19.31%.The company’s quarterly revenue was up 15.0% compared to the same quarter last year. During the same period in the prior year, the business posted $0.32 earnings per share. Equities analysts anticipate that DexCom, Inc. will post 2.55 earnings per share for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of several recent research reports. Raymond James Financial set a $81.00 price target on DexCom in a report on Friday, May 1st. Wall Street Zen upgraded DexCom from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 2nd. Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Mizuho set a $75.00 price target on DexCom in a report on Friday, May 1st. Finally, Piper Sandler reiterated an “overweight” rating on shares of DexCom in a report on Thursday, February 5th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, DexCom presently has a consensus rating of “Moderate Buy” and a consensus target price of $83.50.

Insider Activity at DexCom

In other news, EVP Michael Jon Brown sold 1,700 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was sold at an average price of $63.04, for a total value of $107,168.00. Following the completion of the sale, the executive vice president directly owned 111,204 shares of the company’s stock, valued at $7,010,300.16. This represents a 1.51% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.28% of the stock is currently owned by company insiders.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.